突变的DNMT3A在急性髓性白血病上产生了一个公共的HLADQ结合新抗原
Dyantha I van der Lee1, Eva M Argiro1, Sebastiaan N J Laan1
1Department of Hematology, Leiden University Medical Center, Leiden, Netherlands.
Frontiers in immunology
|March 28, 2025
概括
研究人员在患有DNMT3A-R882H突变的急性髓性白血病 (AML) 患者中确定了一种公共新抗原. 这一发现为开发用于治疗AML的新免疫疗法提供了有希望的目标.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
背景情况:
- 急性髓性白血病 (AML) 经常存在共同的基因突变.
- 从这些突变中获得的新抗原是癌症免疫治疗的有希望的标.
研究的目的:
- 在AML中识别公共的人类白细胞抗原 (HLA) 类II限制新抗原.
- 评估这些新抗原作为免疫治疗点的潜力.
主要方法:
- 选了26种复发性遗传异常,以检测HLAII类结合.
- 从10个重复突变中合成了24个长型新.
- 同培养的天真CD4T细胞与与新酸脉冲的自身树突细胞共培养.
主要成果:
- 隔离的CD4 T细胞克隆识别来自5种遗传异常的新.
- 由T细胞识别的DNMT3A-R882H和RUNX1框架转移突变的鉴定新.
- 在初级AML样本中,通过DNMT3A-R882H新抗原证明了T细胞的激活.
结论:
- 在AML中确定了一个公共的HLAII类受限制的新抗原.
- 这种新抗原在10%的AML患者中被突变编码,是DNMT3A-R882H突变AML的潜在免疫治疗标.
关键词:
在 CD4 T 细胞中.在DNMT3A中,它是DNMT3A.在HLAII类中,HLA是II类.在RUNX1中,使用RUNX1.急性骨髓性白血病 (AML) 是一种急性骨髓性白血病.癌症 免疫力 免疫力免疫疗法 免疫疗法新抗原是一种新抗原.更多相关视频
11:06Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation
Published on: September 20, 2017
5.6K
07:17Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
Published on: August 23, 2024
1.8K
相关概念视频
03:18Non-LTR Retrotransposons
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
02:39lncRNA - Long Non-coding RNAs
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...